CA2113914C - Phospholipid derivative and liposome containing it - Google Patents
Phospholipid derivative and liposome containing it Download PDFInfo
- Publication number
- CA2113914C CA2113914C CA002113914A CA2113914A CA2113914C CA 2113914 C CA2113914 C CA 2113914C CA 002113914 A CA002113914 A CA 002113914A CA 2113914 A CA2113914 A CA 2113914A CA 2113914 C CA2113914 C CA 2113914C
- Authority
- CA
- Canada
- Prior art keywords
- liposome
- group
- phospholipid
- liposome according
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
Abstract
A phospholipid derivative of the following formula (I):
Description
~~.~3914 Our Ref.: MC-4$0 (E-93124) PHOSPHOLIPID DERIVATIVE AND LIPOSOME CONTAINING IT
The present invention relates to a novel phospholipid derivative and a liposome containing it. Particularly, it relates to a novel phospholipid derivative having a polyalkylene glycol moiety having a maleimide group.
A liposome being a lipid vesicle is capable of containing many substances irrespective of whether such substances are water-soluble or hydrophobic and thus is expected to be a prospective carrier especially for a drug delivery system (DDS).
In recent years, for the purpose of imparting a functionality to the liposome in addition to the inherent properties thereof, an attempt has been made to bond (or introduce) a functional compound such as a protein, a peptide, a sugar or a hydrophilic polymer to the liposome surface.
On the other hand, many studies have been made to overcome general drawbacks of a liposome, such as agglomeration and non-specific capture by a '~1~_3914
The present invention relates to a novel phospholipid derivative and a liposome containing it. Particularly, it relates to a novel phospholipid derivative having a polyalkylene glycol moiety having a maleimide group.
A liposome being a lipid vesicle is capable of containing many substances irrespective of whether such substances are water-soluble or hydrophobic and thus is expected to be a prospective carrier especially for a drug delivery system (DDS).
In recent years, for the purpose of imparting a functionality to the liposome in addition to the inherent properties thereof, an attempt has been made to bond (or introduce) a functional compound such as a protein, a peptide, a sugar or a hydrophilic polymer to the liposome surface.
On the other hand, many studies have been made to overcome general drawbacks of a liposome, such as agglomeration and non-specific capture by a '~1~_3914
- 2 -reticuloendothelial system organ such as liver or spleen, and it has been found effective to bond a polyethylene glycol to the liposome (Japanese Unexamined Patent Publications No. 249717/1989 and No. 149512/1990, FEBS
letters, 268,235 (1990)).
Further, for the purpose of imparting the function of protein and the properties of polyethylene glycol, methods have been proposed to produce a liposome which contains both a protein and a polyethylene glycol (BBA, 142, 1062 (1991), and Japanese Unexamined Patent Publication No, 346918/1992).
The former is a method which comprises solubilizing a lipid-modified antibody, a phospholipid, cholesterol and a lipid derivative of polyethylene glycol by means of a surfactant, followed by removing the surfactant by dialysis, to obtain a liposome. However, it is difficult to remove the surfactant completely, and the product will hardly be useful as a drug. Further, it is necessary to carry out the dialysis for a long period of time at a temperature higher than the phase transfer temperature of the lipid, whereby a useful lipid is rather limited especially when an unstable protein is employed for the production.
The latter is a method which comprises preparing a liposome containing maleimide groups, then bonding a protein having thiol groups and further bonding a polyethylene glycol having thiol groups to excess .3 -maleimide groups. While the protein can be bonded under a mild condition, this method has a problem that the production process is cumbersome, since it involves a two step reaction, and it is difficult to independently control the amount of each component to be bonded.
The present inventors have conducted a study to solve such problems of conventional liposomes containing both a protein and a polyalkylene glycol and as a result, have found it possible to readily produce a liposome containing both a protein and a polyalkylene glycol by using, as a liposome-constituting component, a phospholipid derivative having a maleimide group at one end of a polyalkylene glycol and a phosphatidylethanolamine moiety at the other end.
Further, it has been surprisingly found that the liposome containing such a phospholipid derivative can readily be micronized during the process for micronizing the liposome. The present invention has been accomplished on the basis of these discoveries.
Namely, the present invention provides a phospholipid derivative of the following formula (I) and a liposome containing such a derivative:
O
O
S 1 'N-B~i~lv ~ (I) 2 5 G, wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group _. ~~.~391~
having a polyalkylene glycol moiety.
In the accompanying drawings:
Figure 1 is a graph showing the 1H-NMR chart of M-PEG-PE obtained in Example 1.
Figure 2 is a graph showing the results of measurement of the particle size distribution of the M-PEG-PE-containing liposome prepared in Example 3 by a dynamic light scattering method.
Figure 3 is a graph showing the results of measurement of the particle size distribution of the liposome containing no M-PEG-PE, prepared in Comparative Example, by a dynamic light scattering method.
Figure 4 is a photograph showing the reactivity of the antibody-bonded liposome (immuno liposome) prepared in Example 4 to human stomach cancer cells MKN45. The observation was made by a fluorescent microscope using a fluorescent lipid integrated to the liposome, as a marker.
Figure 5 is a photograph showing the reactivity of the non-antibody-bonded liposome prepared in Comparative Example to human stomach cancer cells MKN45. The observation was made by a fluorescent microscope using a fluorescent lipid integrated to the liposome, as a marker.
Figure 6 is a photograph showing the luminous field image of Figure 5.
Now, the present invention will be described in _. X113914 -..5 _ detail.
The phospholipid derivative of the present invention is represented by the above formula (I). The residue of a phospholipid having phosphatidylethanolamine moiety for A, is not particularly limited so long as it is the one having a phosphatidylethanolamino group. However, it may preferably be a group of the following formula (II):
I
O ~ O (II) II II
R ~_ C _ O _ C H - C H z0 - P - O ( C Ei z) zN H D -O
wherein each of R1 and R2 which are independent of each other, is a C11-C19 alkyl group such as a lauroyl group, a myristoyl group, a palmitoyl group or a stearoyl group, or a C11-C19 alkenyl group such as an oleyl group, and D
is a single bond, or a C1-C11 linking group such as -C= ( NHZ+) ( CHZ ) 0-i0-, -CO ( CH2 ) 0_10- or -CH2(CH2)0-10 The linking group having a polyalkylene glycol moiety for B, is not particularly limited so long as it is the one having a polyalkylene glycol unit such as polyethylene glycol, polypropylene glycol, polytetramethylene glycol or polyhexamethylene glycol.
However, it may preferably be a linking group of the following formula (III):
__ ~1~391~
-J-PEG-L- (III) wherein each of J and L which are independent of each other, is a single bond, or a C1-C11 linking group such as -CO ( CH2 ) o-to , ( CH2 ) o-ioCO-, -NHCO ( CH2 ) 0-10 , -(CH2)o-loCONH-, or -CHZ(CH2)o-1o , and PEG is a polyethylene glycol residue such as -(CH2CH20)li-455-Now, a process for producing the phospholipid derivative of the present invention will be described.
The phospholipid derivative of the present invention can be produced, for example, by reacting a lipid having a thiol group with a polyalkylene glycol having two maleimide groups.
O O O
N-~_y~ ._~ A _ S ~N-H--N
A S H +
O . O' O O
In the above formulas, A and B are as defined above.
Now, the process will be described sequentially in detail.
1. Preparation of the phospholipid having a thiol group (hereinafter sometimes referred to simply as "the thiol-modified phospholipid") The thiol-modified phospholipid can be obtained by introducing a thiol group to phosphatidylethanolamine by means of a known amino group-modifying reaction. Namely, it can be produced by dissolving a Traunt reagent such as iminothiolane or a mercapto alkyl imidate and ~1139~4 -7_ phosphatidylethanolamine in an organic solvent such as chloroform or chloroform/methanol (1/1 to 10/1) in the presence of a basic compound such as triethylamine or pyridine and reacting them at a temperature of from 20 to 40°C under a condition of an inner gas such as nitrogen gas or argon gas. Otherwise, it can be prepared by means of a thiol carboxylic acid disclosed in Japanese Unexamined Patent Publication No. 72067/1989. Or, it may be synthesized by bonding a compound inherently containing a sulfur atom, such as N-succinimidyl-3-(2-pyrridyldithio)propionate, to phosphatidylethanolamine, followed by reducing with a large excess amount of a reducing agent such as 2-mercaptoethanol.
The phosphatidylethanolamine to be used here, i.e.
the phospholipid having a phosphatidylethanolamine moiety, for A in the above formula (I), is not particularly limited and may, for example, be natural phosphatidylethanolamine derived from e.g. yolk, dioleyl phosphatidylethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine or distearoyl phosphatidylethanolamine, preferably dipalmitoyl phosphatidylethanolamine.
2. Preparation of the polyalkylene glycol having two maleimide groups (hereinafter sometimes referred to simply as "the maleimide PAG") The process will be described in detail with respect ~~.~3914 _8_ to a case wherein the polyalkylene glycol moiety is polyethylene glycol (hereinafter sometimes referred to simply as "PEG").
The polyethylene glycol derivative having two maleimide groups can be obtained, for example, by dissolving diaminopolyethylene glycol (available from Nippon Oil and Fats or Sigma) and at least two mol times of a maleimide-modifying reagent such as N-(e-maleimidocaproyloxy)succinimide in an organic solvent such as chloroform dehydrated by e.g. molecular sieve, in the presence of a basic compound such as triethylamine or pyridine and reacting them at a temperature of from 20 to 40°C under an atmosphere of an inner gas such as nitrogen gas or argon gas.
In addition to N-(e-maleimidocaproyloxy)succinimide, the maleimide-modifying reagent may, for example, be N-succinimidyl 4-(p-maleimidophenyl)butyrate, N-succinimidyl 4-(p-maleimidophenyl)propionate or N-(y-maleimidobutyryloxy)succinimide, which is commonly used for the preparation of a maleimide derivative of an amino group.
The average molecular weight of the PEG moiety is usually from 500 to 20000, preferably from 2000 to 10000, more preferably from 2000 to 5000. As such PEG, Sunbright~ VFM5001 (Nippon Oil and Fats) or Polyoxyethylenebisamine (Sigma) may specifically be mentioned.
letters, 268,235 (1990)).
Further, for the purpose of imparting the function of protein and the properties of polyethylene glycol, methods have been proposed to produce a liposome which contains both a protein and a polyethylene glycol (BBA, 142, 1062 (1991), and Japanese Unexamined Patent Publication No, 346918/1992).
The former is a method which comprises solubilizing a lipid-modified antibody, a phospholipid, cholesterol and a lipid derivative of polyethylene glycol by means of a surfactant, followed by removing the surfactant by dialysis, to obtain a liposome. However, it is difficult to remove the surfactant completely, and the product will hardly be useful as a drug. Further, it is necessary to carry out the dialysis for a long period of time at a temperature higher than the phase transfer temperature of the lipid, whereby a useful lipid is rather limited especially when an unstable protein is employed for the production.
The latter is a method which comprises preparing a liposome containing maleimide groups, then bonding a protein having thiol groups and further bonding a polyethylene glycol having thiol groups to excess .3 -maleimide groups. While the protein can be bonded under a mild condition, this method has a problem that the production process is cumbersome, since it involves a two step reaction, and it is difficult to independently control the amount of each component to be bonded.
The present inventors have conducted a study to solve such problems of conventional liposomes containing both a protein and a polyalkylene glycol and as a result, have found it possible to readily produce a liposome containing both a protein and a polyalkylene glycol by using, as a liposome-constituting component, a phospholipid derivative having a maleimide group at one end of a polyalkylene glycol and a phosphatidylethanolamine moiety at the other end.
Further, it has been surprisingly found that the liposome containing such a phospholipid derivative can readily be micronized during the process for micronizing the liposome. The present invention has been accomplished on the basis of these discoveries.
Namely, the present invention provides a phospholipid derivative of the following formula (I) and a liposome containing such a derivative:
O
O
S 1 'N-B~i~lv ~ (I) 2 5 G, wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group _. ~~.~391~
having a polyalkylene glycol moiety.
In the accompanying drawings:
Figure 1 is a graph showing the 1H-NMR chart of M-PEG-PE obtained in Example 1.
Figure 2 is a graph showing the results of measurement of the particle size distribution of the M-PEG-PE-containing liposome prepared in Example 3 by a dynamic light scattering method.
Figure 3 is a graph showing the results of measurement of the particle size distribution of the liposome containing no M-PEG-PE, prepared in Comparative Example, by a dynamic light scattering method.
Figure 4 is a photograph showing the reactivity of the antibody-bonded liposome (immuno liposome) prepared in Example 4 to human stomach cancer cells MKN45. The observation was made by a fluorescent microscope using a fluorescent lipid integrated to the liposome, as a marker.
Figure 5 is a photograph showing the reactivity of the non-antibody-bonded liposome prepared in Comparative Example to human stomach cancer cells MKN45. The observation was made by a fluorescent microscope using a fluorescent lipid integrated to the liposome, as a marker.
Figure 6 is a photograph showing the luminous field image of Figure 5.
Now, the present invention will be described in _. X113914 -..5 _ detail.
The phospholipid derivative of the present invention is represented by the above formula (I). The residue of a phospholipid having phosphatidylethanolamine moiety for A, is not particularly limited so long as it is the one having a phosphatidylethanolamino group. However, it may preferably be a group of the following formula (II):
I
O ~ O (II) II II
R ~_ C _ O _ C H - C H z0 - P - O ( C Ei z) zN H D -O
wherein each of R1 and R2 which are independent of each other, is a C11-C19 alkyl group such as a lauroyl group, a myristoyl group, a palmitoyl group or a stearoyl group, or a C11-C19 alkenyl group such as an oleyl group, and D
is a single bond, or a C1-C11 linking group such as -C= ( NHZ+) ( CHZ ) 0-i0-, -CO ( CH2 ) 0_10- or -CH2(CH2)0-10 The linking group having a polyalkylene glycol moiety for B, is not particularly limited so long as it is the one having a polyalkylene glycol unit such as polyethylene glycol, polypropylene glycol, polytetramethylene glycol or polyhexamethylene glycol.
However, it may preferably be a linking group of the following formula (III):
__ ~1~391~
-J-PEG-L- (III) wherein each of J and L which are independent of each other, is a single bond, or a C1-C11 linking group such as -CO ( CH2 ) o-to , ( CH2 ) o-ioCO-, -NHCO ( CH2 ) 0-10 , -(CH2)o-loCONH-, or -CHZ(CH2)o-1o , and PEG is a polyethylene glycol residue such as -(CH2CH20)li-455-Now, a process for producing the phospholipid derivative of the present invention will be described.
The phospholipid derivative of the present invention can be produced, for example, by reacting a lipid having a thiol group with a polyalkylene glycol having two maleimide groups.
O O O
N-~_y~ ._~ A _ S ~N-H--N
A S H +
O . O' O O
In the above formulas, A and B are as defined above.
Now, the process will be described sequentially in detail.
1. Preparation of the phospholipid having a thiol group (hereinafter sometimes referred to simply as "the thiol-modified phospholipid") The thiol-modified phospholipid can be obtained by introducing a thiol group to phosphatidylethanolamine by means of a known amino group-modifying reaction. Namely, it can be produced by dissolving a Traunt reagent such as iminothiolane or a mercapto alkyl imidate and ~1139~4 -7_ phosphatidylethanolamine in an organic solvent such as chloroform or chloroform/methanol (1/1 to 10/1) in the presence of a basic compound such as triethylamine or pyridine and reacting them at a temperature of from 20 to 40°C under a condition of an inner gas such as nitrogen gas or argon gas. Otherwise, it can be prepared by means of a thiol carboxylic acid disclosed in Japanese Unexamined Patent Publication No. 72067/1989. Or, it may be synthesized by bonding a compound inherently containing a sulfur atom, such as N-succinimidyl-3-(2-pyrridyldithio)propionate, to phosphatidylethanolamine, followed by reducing with a large excess amount of a reducing agent such as 2-mercaptoethanol.
The phosphatidylethanolamine to be used here, i.e.
the phospholipid having a phosphatidylethanolamine moiety, for A in the above formula (I), is not particularly limited and may, for example, be natural phosphatidylethanolamine derived from e.g. yolk, dioleyl phosphatidylethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine or distearoyl phosphatidylethanolamine, preferably dipalmitoyl phosphatidylethanolamine.
2. Preparation of the polyalkylene glycol having two maleimide groups (hereinafter sometimes referred to simply as "the maleimide PAG") The process will be described in detail with respect ~~.~3914 _8_ to a case wherein the polyalkylene glycol moiety is polyethylene glycol (hereinafter sometimes referred to simply as "PEG").
The polyethylene glycol derivative having two maleimide groups can be obtained, for example, by dissolving diaminopolyethylene glycol (available from Nippon Oil and Fats or Sigma) and at least two mol times of a maleimide-modifying reagent such as N-(e-maleimidocaproyloxy)succinimide in an organic solvent such as chloroform dehydrated by e.g. molecular sieve, in the presence of a basic compound such as triethylamine or pyridine and reacting them at a temperature of from 20 to 40°C under an atmosphere of an inner gas such as nitrogen gas or argon gas.
In addition to N-(e-maleimidocaproyloxy)succinimide, the maleimide-modifying reagent may, for example, be N-succinimidyl 4-(p-maleimidophenyl)butyrate, N-succinimidyl 4-(p-maleimidophenyl)propionate or N-(y-maleimidobutyryloxy)succinimide, which is commonly used for the preparation of a maleimide derivative of an amino group.
The average molecular weight of the PEG moiety is usually from 500 to 20000, preferably from 2000 to 10000, more preferably from 2000 to 5000. As such PEG, Sunbright~ VFM5001 (Nippon Oil and Fats) or Polyoxyethylenebisamine (Sigma) may specifically be mentioned.
3. Preparation of the compound of the present invention (hereinafter sometimes referred to simply as "M-PAG-PE") M-PAG-PE can be prepared by adding and reacting the thiol-modified phospholipid dissolved in an organic solvent such as chloroform or chloroform/methanol (1/1 to 10/1) to the dimaleimide PAG dissolved in the same solvent in the presence of a basic compound such as triethylamine or pyridine at a temperature of from 0 to 40°C under an atmosphere of an inner gas such as nitrogen gas or argon gas. Here, the thiol-modified phospholipid is gradually added, and its total amount is usually at most an equimolar amount, preferably at most 1/2 mol of the maleimide PAG.
Then, hexane or petroleum ether is added to the reaction solution of M-PAG-PE to precipitate a PAG-containing compound. The precipitate collected by filtration is dried and then dissolved in distilled water at a concentration not lower than the concentration where M-PAG-PE itself forms particles (micell) in the aqueous solution. Insoluble matters are filtered off, and while maintaining the concentration at the above specified level, the solution is subjected to molecular weight fractionation by e.g. an ultrafiltration method, a dialysis method or a gel filtration method to obtain M-PAG-PE. At that time, impurities such as unreacted (excess) dimaleimide PAG are removed. Further, if ~11391~
- .10 -necessary, purification by silica gel column chromatography may further be carried out.
The phospholipid derivative of the present invention thus obtained can be converted to a liposome by a conventional method. The liposome may be formed by a conventional lipid component such as phosphatidylcholine or cholesterol, and M-PAG-PE, or may be formed by mixing such a conventional lipid component, M-PAG-PE and another lipid derivative having a polyethylene glycol moiety as disclosed in e.g. Japanese Unexamined Patent Publication No. 249717/1989 or No. 149512/1990 or FEBS letters, 268,235 (1990).
The phosphatidylcholine useful as the lipid component is not particularly limited and may, for example, be natural phosphatidylcholine derived from e.g. yolk, dioleyl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine or distearyl phosphatidylcholine.
The respective components are used in such proportions that per mol of the phosphatidylcholine, the cholesterol is used in an amount of from 0.3 to 1 mol, preferably from 0.4 to 0.6 mol, and M-PAG-PE is used in an amount of from 0.001 to 0.4 mol, preferably from 0.02 to 0.1 mol. Further, when another lipid derivative having a polyethylene glycol moiety is incorporated, such another lipid derivative is used in an amount of not more than 0.4 mol per mol of the phosphatidylcholine.
~~.139~4 - .11 -Then, the lipid mixture having the solvent removed, may, for example, be hydrated and emulsified by a homogenizer, followed by freezing-thawing to obtain a multilamella liposome (MLV). Further, it may be subjected to super sonic treatment, high speed homogenizing or press-filtration with a membrane having uniform pores (Hope M.J. et al, Biochimica et Biophysica Acta, 812, 55 (1985)) to obtain a single lamella liposome (SUV) and to adjust the particle size to a proper level.
Here, a preferred particle size is from 20 to 300 nm, more preferably from 30 to 200 nm.
Various drugs may be loaded into such a liposome. As such a drug, an antitumor drug such as adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5FU (5-fluorouracil) or acracinomycin, an aminoglucoside such as gentamicin, a (3-lactam antibiotic such as sulpenisillin, a toxin such as ricin A or diphtheria toxin, or an antisense RNA against human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or ras gene, may, for example, be mentioned.
Loading of the drug into the liposome can be conducted by hydrating the lipid with an aqueous drug solution in the case of a water-soluble drug, or by mixing the drug and the lipid in a volatile organic solvent, followed by distilling the solvent off and hydrating the mixture of the drug and the lipid to ~~.~39~~
incorporate the drug into the liposome, in the case of a lipophilic drug.
Further, for the purpose of imparting a functionality to liposome, it is preferred to bond (introduce) a protein, a peptide, a saccharide, a hydrophilic polymer, etc. to the surface of the liposome, as mentioned above.
In the present invention, it is preferred to bond (introduce) various proteins including antibodies or growth factories such as fibroblast growth factor (FGF) and epitheliocyte growth factor (EGF). Particularly preferred are antibodies. The antibodies are those (such as IgA, IgG and IgM) which are reactive with the tissues, cells, bacteria or virus to be treated. For example, polyclonal antibodies of various animals, a mouse monoclonal antibody, a human-mouse chimeric antibody and a human monoclonal antibody may be employed.
To bond such a protein to the liposome, the double bond of the maleimide group of the liposome and the thiol group of the protein can be utilized. Introduction of a thiol group to the protein can be conducted by a method wherein a compound is employed which is commonly used for thiol-modification of a protein and which is reactive with an amino group of the protein, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (Carlsson, J. et al., Biochem. J. 173, 723 (1978)) or iminothiolane, mercaptoalkylimidate (Traut, R. R. et al., Biochemistory, 12, 3266 (1973)). In the case where the protein is an antibody, a method may be employed wherein endogenous dithiol groups in the cystine residues are reduced to thiol groups.
When IgG is employed among antibodies, it may be subjected to F(ab')2 modification by treatment with an enzyme such as pepsin, followed by reduction with e.g.
dithiothreitol to obtain Fab', whereupon thiol groups formed in Fab' are subjected to the bonding reaction with the liposome (Martin, F. J. et al., Biochemistory, 20, 4229 (1981)). In the case of IgM, J-chain may be reduced under a mild condition in accordance with a method of Miller et al. (J. Biol. Chem. 257, 286 (1965)), whereupon thiol groups of Fc moiety of IgMs thereby obtained, are subjected to the bonding reaction with the liposome.
The bonding of the liposome with such a protein can be accomplished by reacting them in a neutral buffer solution (pH 6.0 to 7.5) for from 2 to 16 hours.
To use the liposome of the present invention as a pharmaceutical composition, it may be administered by e~g~ intravascular administration or local administration such as intravesical or intraperitoneal administration against various diseases. The dose may optionally be adjusted depending upon the pharmacological activities, the type of the drug, etc. The pharmaceutical composition usually contains a pharmaceutically acceptable carrier, in addition to the liposome.
- 13a -Now, the present invention will be described in further detail with reference to Examples. However, it should be understood that the present invention is by no ~1~.3914 means restricted to such specific Examples.
Preparation of M-PEG-PE
Preparation of thiol-modified phospholipid 21.8 mg of iminothiolane (manufactured by Sigma Company) was added to 100 mg of dipalmitoyl phosphatidylethanolamine dissolved in 11 ml of a mixture of chloroform/methanol ( 6/5 ) . Then, 50 ~cl of triethylamine was further added thereto, and the mixture was stirred and reacted at room temperature in nitrogen gas until the ninhydrin reaction became negative.
Formation of the thiol-modified phospholipid was confirmed by adding fluoresce maleimide (manufactured by Funakoshi) to a part of the reaction solution, reacting them at room temperature for 40 minutes and observing a fresh yellow fluorescent spot on a thin layer chromatography.
Preparation of dimaleimide PEG
810 mg of diamino polyethylene glycol (Sunbright~
VFM5001 (manufactured by Nippon Oil and Fats); average molecular weight: 5000) was dissolved in 5 ml of chloroform dehydrated by a molecular sieve, and 100 mg of N-(e-maleimidocaproyloxy)succinimide and 50 ~cl of triethyamine were added thereto. The mixture was stirred and reacted at room temperature in nitrogen gas.
Formation of dimaleimide PEG was ascertained by confirming that the ninhydrin reaction became negative.
E
Bonding and purification To 4 ml of the above dimaleimide PEG solution diluted to 30 ml with chloroform, 10 ml of the above thiol-modified phospholipid solution was gradually added, and the mixture was stirred at room temperature for 3 hours under a nitrogen gas condition. To 20 ml of the reaction solution thus obtained, an adequate amount of hexane was added to form a precipitate containing M-PEG-PE. The precipitate was vacuum-dried, whereupon the weight was 330 mg. It was dissolved in 10 ml of distilled water, and insoluble substances were removed by centrifugal separation of 16000 X g for 5 minutes. Further, the same amount of distilled water was added, and concentration-filtration was repeated by means of Centricori 100 (manufactured by Amicon) equipped with an ultra filter membrane with a molecule weight fraction of 100k. By this purification process, PEG not combined with the lipid derivative, was filtered off.
Measurement b~ NMR
2p As shown by the 1H-NMR chart of the desired product in Figure 1, a signal of I.54 ppm of the alkyl ,chain proton of the phospholipid, a signal of 3.57 ppm attributable to -CH2CH20- of PEG and a signal of 6.61 ppm attributable to the double bond of the maleimide, were confirmed.
Reference Example 1 As shown in Example 1, the phospholipid derivative of *Trade-mark z~~39~~
the present invention was considered to behave as a molecular aggregate in the aqueous solution. Therefore, the form of M-PEG-PE in the aqueous solution was studied.
M-PEG-PE dissolved in distilled water at-a concentration of 0.5 mg/ml, was measured by a dynamic light scattering method (ELS-800, manufactured by Otsuka Denshi), whereby particles of 24.8 nm (g (GAMMA) distribution) were observed.
Measurement of maleimide The maleimide content of M-PEG-PE obtained in Example 1 was determined by adding cysteine to the aqueous solution and quantitatively analyzing the SH amount consumed by the maleimide by means of 4,4'-dithiopyridine. Namely, an aqueous solution containing 1.1 mg/ml of M-PEG-PE was mixed in the following proportion, and the mixture was reacted at room temperature for 30 minutes.
1~ EDTA-containing O.1M
phosphate buffer (pH 6.0) 800,u1 0.5mM cysteine 1001 After the reaction, 40 ~1 of 5mM 4,4'-dithiopyridine was added to 960 ~1 of the above solution, and the maleimide content was determined by comparing the change in the absorbance at 324 nm by the color developed by the _. 2113 14 _ .17 -reaction with the remaining cysteine, with that of the control sample (a mole absorbance coefficient of the developed color of 19800/M was employed).
As a result, a maleimide amount of 0.17 ~mol per mg of M-PEG-PE was detected.
Preparation of liposome containing M-PEG-PE
50 mg of dipalmitoyl phosphatidylcholine, 14.6 mg of cholesterol, 10.7 mg of M-PEG-PE and 0.16 mg of FITC-DPPE
(1,2-Dihecadecanoyl-sn-glycero-3-phospho[N-(5-fluoresceinthiocarbamoyl)]ethanolamine, manufactured by Sigma) as a fat-solble marker, were dissolved uniformly in chloroform, and the solvent was removed by an evaporator to form a lipid film. Further, the film was dried under reduced pressure by a vacuum pump for 2.5 hours, and then a O.1M phosphate buffer solution (pH 6.0) and 1 ml of 1mM EDTA were added thereto, the mixture was stirred and hydrated by a voltex mixer. Then, freezing-thawing was repeated five times by means of liquid nitrogen and warm bath of 65°C, to obtain a milky white multilamella liposome (MLV).
Then, 0.5 ml of the above MLV was adjusted to 1 ml with the above buffer solution and subjected to super-sonic treatment for 10 minutes by a Probe-type sonicater (Sonifier 450, manufacture by Branson Company) at an output of 20~, to obtain a transparent small diameter liposome (SW solution). Figure 2 shows the particle - ,18 -size distribution of the liposome thus obtained, as measured by a dynamic light scattering method, it is shown that there was no inclusion of particles having a diameter of more than 1 ~cm.
COMPARATIVE EXAMPLE
MLV was prepared in the same manner~as in Example 3 except that the lipid composition did not contain M-PEG-PE. Supersonic treatment for 10 minutes was repeated twice in the same manner, and then the particle size distribution was measured by a dynamic light scattering method. The results are shown in Figure 3. Particles having a diameter of more than 1 gum were included, thus indicating that no adequate micronization was accomplished.
EXAMPLE 4.
Bonding of an antibody to the M-PEG-PE-containing liposome To an antitumor human monoclonal antibody (IgG; GAB
disclosed in EP 0520499 A), 1/40 mol amount of pepsine (Cooper Biomedical) in O.1M acetic acid buffer solution (pH 4.0), was added, and the mixture was reacted at 37°C
over night for digestion to obtain F(ab')2.
Farther, by chromatography separation with a cation exchange resin (Mono S; manufactured by Pharmacia), F(ab')2 was isolated. The preparation was conducted by a linear gradient from OM to 1.0M NaCl in a O.1M acetic acid buffer solution (pH 4.0), to obtain F(ab')2.
*Trade-mark _ 19 _ 21~.39~~
The buffer solution was changed to a 50mM phosphate buffer solution (pH 7.5) and 1mM EDTA in a PD-10 column (manufacture by Pharmacia) to obtain a solution having an antibody concentration of 2.4 mg/ml. Then, iminothiolane (3 mg/ml) was added thereto in an amount corresponding to
Then, hexane or petroleum ether is added to the reaction solution of M-PAG-PE to precipitate a PAG-containing compound. The precipitate collected by filtration is dried and then dissolved in distilled water at a concentration not lower than the concentration where M-PAG-PE itself forms particles (micell) in the aqueous solution. Insoluble matters are filtered off, and while maintaining the concentration at the above specified level, the solution is subjected to molecular weight fractionation by e.g. an ultrafiltration method, a dialysis method or a gel filtration method to obtain M-PAG-PE. At that time, impurities such as unreacted (excess) dimaleimide PAG are removed. Further, if ~11391~
- .10 -necessary, purification by silica gel column chromatography may further be carried out.
The phospholipid derivative of the present invention thus obtained can be converted to a liposome by a conventional method. The liposome may be formed by a conventional lipid component such as phosphatidylcholine or cholesterol, and M-PAG-PE, or may be formed by mixing such a conventional lipid component, M-PAG-PE and another lipid derivative having a polyethylene glycol moiety as disclosed in e.g. Japanese Unexamined Patent Publication No. 249717/1989 or No. 149512/1990 or FEBS letters, 268,235 (1990).
The phosphatidylcholine useful as the lipid component is not particularly limited and may, for example, be natural phosphatidylcholine derived from e.g. yolk, dioleyl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine or distearyl phosphatidylcholine.
The respective components are used in such proportions that per mol of the phosphatidylcholine, the cholesterol is used in an amount of from 0.3 to 1 mol, preferably from 0.4 to 0.6 mol, and M-PAG-PE is used in an amount of from 0.001 to 0.4 mol, preferably from 0.02 to 0.1 mol. Further, when another lipid derivative having a polyethylene glycol moiety is incorporated, such another lipid derivative is used in an amount of not more than 0.4 mol per mol of the phosphatidylcholine.
~~.139~4 - .11 -Then, the lipid mixture having the solvent removed, may, for example, be hydrated and emulsified by a homogenizer, followed by freezing-thawing to obtain a multilamella liposome (MLV). Further, it may be subjected to super sonic treatment, high speed homogenizing or press-filtration with a membrane having uniform pores (Hope M.J. et al, Biochimica et Biophysica Acta, 812, 55 (1985)) to obtain a single lamella liposome (SUV) and to adjust the particle size to a proper level.
Here, a preferred particle size is from 20 to 300 nm, more preferably from 30 to 200 nm.
Various drugs may be loaded into such a liposome. As such a drug, an antitumor drug such as adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5FU (5-fluorouracil) or acracinomycin, an aminoglucoside such as gentamicin, a (3-lactam antibiotic such as sulpenisillin, a toxin such as ricin A or diphtheria toxin, or an antisense RNA against human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or ras gene, may, for example, be mentioned.
Loading of the drug into the liposome can be conducted by hydrating the lipid with an aqueous drug solution in the case of a water-soluble drug, or by mixing the drug and the lipid in a volatile organic solvent, followed by distilling the solvent off and hydrating the mixture of the drug and the lipid to ~~.~39~~
incorporate the drug into the liposome, in the case of a lipophilic drug.
Further, for the purpose of imparting a functionality to liposome, it is preferred to bond (introduce) a protein, a peptide, a saccharide, a hydrophilic polymer, etc. to the surface of the liposome, as mentioned above.
In the present invention, it is preferred to bond (introduce) various proteins including antibodies or growth factories such as fibroblast growth factor (FGF) and epitheliocyte growth factor (EGF). Particularly preferred are antibodies. The antibodies are those (such as IgA, IgG and IgM) which are reactive with the tissues, cells, bacteria or virus to be treated. For example, polyclonal antibodies of various animals, a mouse monoclonal antibody, a human-mouse chimeric antibody and a human monoclonal antibody may be employed.
To bond such a protein to the liposome, the double bond of the maleimide group of the liposome and the thiol group of the protein can be utilized. Introduction of a thiol group to the protein can be conducted by a method wherein a compound is employed which is commonly used for thiol-modification of a protein and which is reactive with an amino group of the protein, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (Carlsson, J. et al., Biochem. J. 173, 723 (1978)) or iminothiolane, mercaptoalkylimidate (Traut, R. R. et al., Biochemistory, 12, 3266 (1973)). In the case where the protein is an antibody, a method may be employed wherein endogenous dithiol groups in the cystine residues are reduced to thiol groups.
When IgG is employed among antibodies, it may be subjected to F(ab')2 modification by treatment with an enzyme such as pepsin, followed by reduction with e.g.
dithiothreitol to obtain Fab', whereupon thiol groups formed in Fab' are subjected to the bonding reaction with the liposome (Martin, F. J. et al., Biochemistory, 20, 4229 (1981)). In the case of IgM, J-chain may be reduced under a mild condition in accordance with a method of Miller et al. (J. Biol. Chem. 257, 286 (1965)), whereupon thiol groups of Fc moiety of IgMs thereby obtained, are subjected to the bonding reaction with the liposome.
The bonding of the liposome with such a protein can be accomplished by reacting them in a neutral buffer solution (pH 6.0 to 7.5) for from 2 to 16 hours.
To use the liposome of the present invention as a pharmaceutical composition, it may be administered by e~g~ intravascular administration or local administration such as intravesical or intraperitoneal administration against various diseases. The dose may optionally be adjusted depending upon the pharmacological activities, the type of the drug, etc. The pharmaceutical composition usually contains a pharmaceutically acceptable carrier, in addition to the liposome.
- 13a -Now, the present invention will be described in further detail with reference to Examples. However, it should be understood that the present invention is by no ~1~.3914 means restricted to such specific Examples.
Preparation of M-PEG-PE
Preparation of thiol-modified phospholipid 21.8 mg of iminothiolane (manufactured by Sigma Company) was added to 100 mg of dipalmitoyl phosphatidylethanolamine dissolved in 11 ml of a mixture of chloroform/methanol ( 6/5 ) . Then, 50 ~cl of triethylamine was further added thereto, and the mixture was stirred and reacted at room temperature in nitrogen gas until the ninhydrin reaction became negative.
Formation of the thiol-modified phospholipid was confirmed by adding fluoresce maleimide (manufactured by Funakoshi) to a part of the reaction solution, reacting them at room temperature for 40 minutes and observing a fresh yellow fluorescent spot on a thin layer chromatography.
Preparation of dimaleimide PEG
810 mg of diamino polyethylene glycol (Sunbright~
VFM5001 (manufactured by Nippon Oil and Fats); average molecular weight: 5000) was dissolved in 5 ml of chloroform dehydrated by a molecular sieve, and 100 mg of N-(e-maleimidocaproyloxy)succinimide and 50 ~cl of triethyamine were added thereto. The mixture was stirred and reacted at room temperature in nitrogen gas.
Formation of dimaleimide PEG was ascertained by confirming that the ninhydrin reaction became negative.
E
Bonding and purification To 4 ml of the above dimaleimide PEG solution diluted to 30 ml with chloroform, 10 ml of the above thiol-modified phospholipid solution was gradually added, and the mixture was stirred at room temperature for 3 hours under a nitrogen gas condition. To 20 ml of the reaction solution thus obtained, an adequate amount of hexane was added to form a precipitate containing M-PEG-PE. The precipitate was vacuum-dried, whereupon the weight was 330 mg. It was dissolved in 10 ml of distilled water, and insoluble substances were removed by centrifugal separation of 16000 X g for 5 minutes. Further, the same amount of distilled water was added, and concentration-filtration was repeated by means of Centricori 100 (manufactured by Amicon) equipped with an ultra filter membrane with a molecule weight fraction of 100k. By this purification process, PEG not combined with the lipid derivative, was filtered off.
Measurement b~ NMR
2p As shown by the 1H-NMR chart of the desired product in Figure 1, a signal of I.54 ppm of the alkyl ,chain proton of the phospholipid, a signal of 3.57 ppm attributable to -CH2CH20- of PEG and a signal of 6.61 ppm attributable to the double bond of the maleimide, were confirmed.
Reference Example 1 As shown in Example 1, the phospholipid derivative of *Trade-mark z~~39~~
the present invention was considered to behave as a molecular aggregate in the aqueous solution. Therefore, the form of M-PEG-PE in the aqueous solution was studied.
M-PEG-PE dissolved in distilled water at-a concentration of 0.5 mg/ml, was measured by a dynamic light scattering method (ELS-800, manufactured by Otsuka Denshi), whereby particles of 24.8 nm (g (GAMMA) distribution) were observed.
Measurement of maleimide The maleimide content of M-PEG-PE obtained in Example 1 was determined by adding cysteine to the aqueous solution and quantitatively analyzing the SH amount consumed by the maleimide by means of 4,4'-dithiopyridine. Namely, an aqueous solution containing 1.1 mg/ml of M-PEG-PE was mixed in the following proportion, and the mixture was reacted at room temperature for 30 minutes.
1~ EDTA-containing O.1M
phosphate buffer (pH 6.0) 800,u1 0.5mM cysteine 1001 After the reaction, 40 ~1 of 5mM 4,4'-dithiopyridine was added to 960 ~1 of the above solution, and the maleimide content was determined by comparing the change in the absorbance at 324 nm by the color developed by the _. 2113 14 _ .17 -reaction with the remaining cysteine, with that of the control sample (a mole absorbance coefficient of the developed color of 19800/M was employed).
As a result, a maleimide amount of 0.17 ~mol per mg of M-PEG-PE was detected.
Preparation of liposome containing M-PEG-PE
50 mg of dipalmitoyl phosphatidylcholine, 14.6 mg of cholesterol, 10.7 mg of M-PEG-PE and 0.16 mg of FITC-DPPE
(1,2-Dihecadecanoyl-sn-glycero-3-phospho[N-(5-fluoresceinthiocarbamoyl)]ethanolamine, manufactured by Sigma) as a fat-solble marker, were dissolved uniformly in chloroform, and the solvent was removed by an evaporator to form a lipid film. Further, the film was dried under reduced pressure by a vacuum pump for 2.5 hours, and then a O.1M phosphate buffer solution (pH 6.0) and 1 ml of 1mM EDTA were added thereto, the mixture was stirred and hydrated by a voltex mixer. Then, freezing-thawing was repeated five times by means of liquid nitrogen and warm bath of 65°C, to obtain a milky white multilamella liposome (MLV).
Then, 0.5 ml of the above MLV was adjusted to 1 ml with the above buffer solution and subjected to super-sonic treatment for 10 minutes by a Probe-type sonicater (Sonifier 450, manufacture by Branson Company) at an output of 20~, to obtain a transparent small diameter liposome (SW solution). Figure 2 shows the particle - ,18 -size distribution of the liposome thus obtained, as measured by a dynamic light scattering method, it is shown that there was no inclusion of particles having a diameter of more than 1 ~cm.
COMPARATIVE EXAMPLE
MLV was prepared in the same manner~as in Example 3 except that the lipid composition did not contain M-PEG-PE. Supersonic treatment for 10 minutes was repeated twice in the same manner, and then the particle size distribution was measured by a dynamic light scattering method. The results are shown in Figure 3. Particles having a diameter of more than 1 gum were included, thus indicating that no adequate micronization was accomplished.
EXAMPLE 4.
Bonding of an antibody to the M-PEG-PE-containing liposome To an antitumor human monoclonal antibody (IgG; GAB
disclosed in EP 0520499 A), 1/40 mol amount of pepsine (Cooper Biomedical) in O.1M acetic acid buffer solution (pH 4.0), was added, and the mixture was reacted at 37°C
over night for digestion to obtain F(ab')2.
Farther, by chromatography separation with a cation exchange resin (Mono S; manufactured by Pharmacia), F(ab')2 was isolated. The preparation was conducted by a linear gradient from OM to 1.0M NaCl in a O.1M acetic acid buffer solution (pH 4.0), to obtain F(ab')2.
*Trade-mark _ 19 _ 21~.39~~
The buffer solution was changed to a 50mM phosphate buffer solution (pH 7.5) and 1mM EDTA in a PD-10 column (manufacture by Pharmacia) to obtain a solution having an antibody concentration of 2.4 mg/ml. Then, iminothiolane (3 mg/ml) was added thereto in an amount corresponding to
4 mol times of the antibody, and the mixture was reacted at 37°C for one hour. Unreacted iminothiolane was removed by demineralization by a PD-10 column equilibrated with a O.1M phosphate buffer solution (pH
6.0) and 1mM EDTA, to obtain 1.9 mg/ml of a thiol-modified antibody.
To 0.7 ml of this antibody, 0.42 ml of the SUV
liposome obtained in Example 3, was added, and the mixture was shaked at room temperature over night to obtain an immunoliposome.
Reactivity to the target cells Using human gastric cancer cell line MKN 45 (having a reactivity with the antibody used in Example 4) which was cultured on a slide chamber (Lab-Tek~ chamber, manufactured by Nunc, Inc.) and fixed by paraformaldehyde, the reactivity of the immunoliposome prepared in Example 4, was confirmed. A reaction solution comprising 50 ~1 of the liposome solution, 150 ,~1 of a human serum and 50 ,u1 of a 10 mM phosphate buffer solution (pH 7.4) and 0.15M NaCl, was added to the cells, and the mixture was incubated at 37°C for 30 minutes.
- ~20 -After washing with the same buffer solution, fluorescence of FITC-DPPE (as mentioned above) introduced as a marker, was observed by a fluorescence microscope (confocal microscope adapter VX100, manufactured by Newportj. The respective fluorescence microscopic photographs are shown in Figure 4 (antibody-bonded liposome), Figure 5 (non antibody-bonded liposome prepared in Comparative Example) and Figure 6 (Luminous field image of Figure 5). As compared with the liposome used as control, high reactivity of the immuno liposome of the present invention to MKN95 cells was confirmed.
The phospholipid derivative of the present invention is useful as~a phospholipid component constituting a liposome, and the liposome employing the phospholipid derivative has a polyalkylene glycol moiety, whereby non-specific uptake by a recticuloendothelial.system such as liver or spleen can be suppressed and at the same time the liposome can be readily bonded to a protein having thiol moiety. Further, by means of the phospholipid derivative of the present invention, the liposome can readily be micronized.
6.0) and 1mM EDTA, to obtain 1.9 mg/ml of a thiol-modified antibody.
To 0.7 ml of this antibody, 0.42 ml of the SUV
liposome obtained in Example 3, was added, and the mixture was shaked at room temperature over night to obtain an immunoliposome.
Reactivity to the target cells Using human gastric cancer cell line MKN 45 (having a reactivity with the antibody used in Example 4) which was cultured on a slide chamber (Lab-Tek~ chamber, manufactured by Nunc, Inc.) and fixed by paraformaldehyde, the reactivity of the immunoliposome prepared in Example 4, was confirmed. A reaction solution comprising 50 ~1 of the liposome solution, 150 ,~1 of a human serum and 50 ,u1 of a 10 mM phosphate buffer solution (pH 7.4) and 0.15M NaCl, was added to the cells, and the mixture was incubated at 37°C for 30 minutes.
- ~20 -After washing with the same buffer solution, fluorescence of FITC-DPPE (as mentioned above) introduced as a marker, was observed by a fluorescence microscope (confocal microscope adapter VX100, manufactured by Newportj. The respective fluorescence microscopic photographs are shown in Figure 4 (antibody-bonded liposome), Figure 5 (non antibody-bonded liposome prepared in Comparative Example) and Figure 6 (Luminous field image of Figure 5). As compared with the liposome used as control, high reactivity of the immuno liposome of the present invention to MKN95 cells was confirmed.
The phospholipid derivative of the present invention is useful as~a phospholipid component constituting a liposome, and the liposome employing the phospholipid derivative has a polyalkylene glycol moiety, whereby non-specific uptake by a recticuloendothelial.system such as liver or spleen can be suppressed and at the same time the liposome can be readily bonded to a protein having thiol moiety. Further, by means of the phospholipid derivative of the present invention, the liposome can readily be micronized.
Claims (14)
1. A phospholipid derivative of the following formula (I):
wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group having a polyalkylene glycol moiety.
wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group having a polyalkylene glycol moiety.
2. The phospholipid derivative according to Claim 1, wherein the residue of a phospholipid having a phosphatidylethanolamine moiety is of the following formula (II):
wherein each of R1 and R2 which are independent of each other, is a C11-C19 alkyl group or a C11-C19 alkenyl group, and D is a single bond, or a C1-C11 linking group.
wherein each of R1 and R2 which are independent of each other, is a C11-C19 alkyl group or a C11-C19 alkenyl group, and D is a single bond, or a C1-C11 linking group.
3. The phospholipid derivative according to Claim 1, wherein the liking group having a polyalkylene glycol moiety is of the following formula (III):
-J-PEG-L- (III) wherein each of J and L which are independent of each other, is a single bond, or a C1-C11 linking group, and PEG is a polyethylene glycol residue.
-J-PEG-L- (III) wherein each of J and L which are independent of each other, is a single bond, or a C1-C11 linking group, and PEG is a polyethylene glycol residue.
9. A liposome containing a phospholipid derivative of the following formula (I):
wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group having a polyalkylene glycol moiety.
wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group having a polyalkylene glycol moiety.
5. The liposome according to Claim 4 having a thiol group-imparted protein bonded via the phospholipid derivative.
6. The liposome according to Claim 4 having a thiol group-imparted protein bonded via a double bond of a maleimide group of the phospholipid derivative.
7. The liposome according to Claim 4 having a drug loaded.
8. The liposome according to Claim 7, wherein the drug is an antitumor drug.
9. The liposome according to Claim 8, wherein the antitumor drug is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5-fluorouracil and acracinomycin.
10. The liposome according to Claim 5 or 6 having a drug loaded.
11. The liposome according to Claim 10, wherein the drug is an antitumor drug.
12. The liposome according to Claim 11, wherein the antitumor drug is selected from the group consisting of adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5-fluorouracil and acracinomycin.
13. The liposome according to Claim 5, 6, 10, 11 or 12, wherein the thiol group-imparted protein is an antibody wherein endogenous dithiol groups in cistine residues thereof having been reduced to thiol groups.
14. A pharmaceutical composition comprising an effective amount of the liposome according to Claim 7, 8, 9, 10, 11, 12 or 13 and a pharmaceutically acceptable carrier thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27651/1993 | 1993-01-22 | ||
JP02765193A JP3351476B2 (en) | 1993-01-22 | 1993-01-22 | Phospholipid derivatives and liposomes containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2113914A1 CA2113914A1 (en) | 1994-07-23 |
CA2113914C true CA2113914C (en) | 2003-07-29 |
Family
ID=12226829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002113914A Expired - Fee Related CA2113914C (en) | 1993-01-22 | 1994-01-20 | Phospholipid derivative and liposome containing it |
Country Status (6)
Country | Link |
---|---|
US (2) | US5556948A (en) |
EP (1) | EP0607978B1 (en) |
JP (1) | JP3351476B2 (en) |
CA (1) | CA2113914C (en) |
DE (1) | DE69421631T2 (en) |
ES (1) | ES2140473T3 (en) |
Families Citing this family (269)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
KR19990029749A (en) * | 1997-09-17 | 1999-04-26 | 미우라 아끼라 | Divalent reactive water soluble polymer derivatives and composites containing them |
US6083923A (en) * | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
US5990274A (en) * | 1997-11-25 | 1999-11-23 | Dade Behring Inc. | Cyclosporine derivatives and uses thereof |
AU751434B2 (en) * | 1997-12-23 | 2002-08-15 | Inex Pharmaceuticals Corporation | Polyamide oligomers |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
AU764144B2 (en) | 1998-08-28 | 2003-08-14 | Gryphon Therapeutics, Inc. | Polyamide chains of precise length, methods to manufacture them and their conjugates |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
ES2265340T3 (en) * | 1999-04-23 | 2007-02-16 | Mitsubishi Chemical Corporation | ANTIBODY AND LIPOSOMA LINKED TO A POLYCHYLENGLYCOL. |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
DK2000545T3 (en) | 2001-06-20 | 2011-11-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of lung tumor |
CA2451643C (en) | 2001-06-21 | 2012-11-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
DE60223047T2 (en) | 2001-08-22 | 2008-07-24 | Bioartificial Gel Technologies Inc., Montreal | PROCESS FOR PREPARING ACTIVATED POLYETHYLENE GLYCOLS |
CA2460120A1 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
ATE516364T1 (en) | 2001-10-09 | 2011-07-15 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEY S 5 |
GB0125659D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Spermicides |
AU2002368202B2 (en) | 2001-11-02 | 2008-06-05 | Insert Therapeutics, Inc | Methods and compositions for therapeutic use of RNA interference |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
JP2005525095A (en) | 2002-01-02 | 2005-08-25 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
US20050163832A1 (en) * | 2002-02-13 | 2005-07-28 | Vladimir Torchilin | Intracellular delivery of therapeutic agents |
US20030203481A1 (en) * | 2002-02-25 | 2003-10-30 | Surber Mark W. | Conjugated minicells |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
AU2003230874A1 (en) | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
WO2003099830A2 (en) * | 2002-05-24 | 2003-12-04 | Neopharm, Inc. | Cardiolipin compositions, methods of preparation and use |
EA200401565A1 (en) * | 2002-05-24 | 2005-04-28 | Неофарм, Инк. | METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS) |
US7655772B2 (en) | 2002-09-06 | 2010-02-02 | University Of South Florida | Materials and methods for treatment of allergic diseases |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
BR0314236A (en) * | 2002-09-13 | 2005-08-09 | Replicor Inc | Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
AU2002353814A1 (en) * | 2002-10-15 | 2004-05-04 | Baxter Healthcare S.A. | Process for the preparation of polyethylene glycol bis amine |
US20050277611A1 (en) * | 2002-10-16 | 2005-12-15 | Neopharm, Inc. | Cationic cardiolipin analoges and its use thereof |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
WO2004044138A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
JP4986109B2 (en) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | Antisense regulation of apolipoprotein B expression |
DK1569695T3 (en) | 2002-11-13 | 2013-08-05 | Genzyme Corp | ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
DK1597366T3 (en) | 2003-02-11 | 2013-02-25 | Antisense Therapeutics Ltd | Modulation of expression of insulin-like growth factor receptor I |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
EP1620112A4 (en) * | 2003-04-17 | 2007-04-25 | Univ Columbia | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
SG146682A1 (en) | 2003-09-18 | 2008-10-30 | Isis Pharmaceuticals Inc | Modulation of eif4e expression |
US7662929B2 (en) | 2003-10-10 | 2010-02-16 | Alchemia Oncology Pty Limited | Antibody that specifically binds hyaluronan synthase |
US7960350B2 (en) * | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
CA2747871C (en) | 2003-11-17 | 2018-04-10 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
CA2559853A1 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
EP2365077B1 (en) * | 2004-03-12 | 2013-05-08 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
EP2700720A3 (en) | 2004-03-15 | 2015-01-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNASE H |
CA2561221C (en) * | 2004-03-26 | 2016-09-20 | Curis, Inc. | Rna interference modulators of hedgehog signaling and uses thereof |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
ATE514776T1 (en) | 2004-10-05 | 2011-07-15 | California Inst Of Techn | APTAMER-REGULATED NUCLEIC ACIDS AND USES THEREOF |
AU2005316384B2 (en) * | 2004-12-14 | 2012-02-09 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
RU2007137489A (en) | 2005-03-10 | 2009-04-20 | Дженентек, Инк. (Us) | METHODS AND COMPOSITIONS FOR MODULATION OF VESSEL INTEGRITY |
ATE541928T1 (en) | 2005-03-31 | 2012-02-15 | Calando Pharmaceuticals Inc | RIBONUCLEOTIDE REDUCTASE SUBUNITY 2 INHIBITORS AND USES THEREOF |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
CA2630602A1 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
SI2161038T1 (en) | 2006-01-26 | 2014-05-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
AU2007233109B2 (en) | 2006-03-31 | 2010-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
WO2007127272A2 (en) * | 2006-04-24 | 2007-11-08 | The Cbr Institute For Biomedical Research | Method of producing immunoliposomes and compositions thereof |
EP2051585A4 (en) * | 2006-04-28 | 2010-06-02 | Univ South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
WO2007127428A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
EP2013222B1 (en) * | 2006-04-28 | 2013-02-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the jc virus |
CN101437943A (en) | 2006-05-03 | 2009-05-20 | 波罗的科技发展有限公司 | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
BRPI0712034A2 (en) | 2006-05-19 | 2012-01-10 | Alnylam Pharmaceuticals Inc | aha rnai modulation and therapeutic uses thereof |
EP2192200B1 (en) | 2006-05-22 | 2012-10-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
CA2600220C (en) * | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
WO2008058291A2 (en) * | 2006-11-09 | 2008-05-15 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
EP2118118B1 (en) * | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
WO2008091655A2 (en) * | 2007-01-23 | 2008-07-31 | The Regents Of The University Of California | Methods, compositions and device for directed and controlled heating and release of agents |
WO2008094945A2 (en) | 2007-01-29 | 2008-08-07 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
CN101663407B (en) | 2007-02-22 | 2017-08-08 | 健泰科生物技术公司 | method for detecting inflammatory bowel disease |
JP5350360B2 (en) | 2007-03-29 | 2013-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibiting the expression of genes from Ebola |
AR066984A1 (en) | 2007-06-15 | 2009-09-23 | Novartis Ag | INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA) |
WO2009011855A2 (en) * | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
US8367815B2 (en) * | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US20120165387A1 (en) | 2007-08-28 | 2012-06-28 | Smolke Christina D | General composition framework for ligand-controlled RNA regulatory systems |
US8865667B2 (en) * | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
JP2010539978A (en) | 2007-10-02 | 2010-12-24 | アムジェン インコーポレイテッド | Increased erythropoietin using nucleic acids that can hybridize to micro-RNA and its precursors |
US9029524B2 (en) * | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
EP2848688A1 (en) | 2007-12-10 | 2015-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
CN102016036B (en) | 2008-02-11 | 2015-04-08 | 阿克赛医药公司 | Modified RNAi polynucleotides and uses thereof |
KR101397407B1 (en) | 2008-03-05 | 2014-06-19 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
EP2283133A2 (en) | 2008-04-04 | 2011-02-16 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
US20100003315A1 (en) | 2008-07-02 | 2010-01-07 | Willeford Kenneth L | Method and Composition for the Treatment of Skin Conditions |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
JP5420668B2 (en) | 2008-08-25 | 2014-02-19 | エクスカリアード・ファーマシューティカルズ,インコーポレイテッド | Antisense oligonucleotides for connective tissue growth factor and uses thereof |
EP2331690B1 (en) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of mutant egfr gene |
CA2753338A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
EP3109321B1 (en) | 2008-09-25 | 2019-05-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
EP3848461A1 (en) | 2008-10-20 | 2021-07-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
WO2010068414A2 (en) * | 2008-11-25 | 2010-06-17 | Bowen Richard L | Methods for treating obesity related disease |
WO2010065662A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
KR101829469B1 (en) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
RU2746478C2 (en) | 2008-12-04 | 2021-04-14 | КьюРНА, Инк. | Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene |
JP5855462B2 (en) | 2008-12-10 | 2016-02-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | DsRNA compositions targeting GNAQ and methods for inhibiting expression |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
ES2658626T3 (en) | 2009-02-12 | 2018-03-12 | Curna, Inc. | Treatment of diseases related to glial cell-derived neurotrophic factor (GDNF) by inhibition of natural antisense transcript to GDNF |
KR101682735B1 (en) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
JP6250263B2 (en) | 2009-03-04 | 2017-12-20 | クルナ・インコーポレーテッド | Treatment of SIRT1-related diseases by suppression of natural antisense transcripts against sirtuin 1 (SIRT1) |
EP2406376A1 (en) | 2009-03-12 | 2012-01-18 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
ES2656290T3 (en) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
EP2424987B1 (en) | 2009-05-01 | 2017-11-15 | CuRNA, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
JP5883782B2 (en) | 2009-05-06 | 2016-03-15 | クルナ・インコーポレーテッド | Treatment of lipid transport metabolism gene-related diseases by suppression of natural antisense transcripts on lipid transport metabolism genes |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
CN103221541B (en) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
US8859515B2 (en) | 2009-06-24 | 2014-10-14 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 |
EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CA2780741C (en) | 2009-10-12 | 2023-04-04 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
WO2011056234A1 (en) | 2009-11-06 | 2011-05-12 | Fibrogen, Inc. | Treatment for radiation-induced disorders |
TWI507524B (en) | 2009-11-30 | 2015-11-11 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
AU2010329847A1 (en) | 2009-12-11 | 2012-07-26 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
RU2619185C2 (en) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2 |
KR101891352B1 (en) | 2009-12-23 | 2018-08-24 | 큐알엔에이, 인크. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
JP5982288B2 (en) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63) |
EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2664866T3 (en) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg |
US8883739B2 (en) | 2010-01-19 | 2014-11-11 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
CA2786568A1 (en) | 2010-01-25 | 2011-07-28 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
JP5976548B2 (en) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcripts against PYCR1 |
SG183335A1 (en) | 2010-02-23 | 2012-09-27 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
CA2794189C (en) | 2010-03-24 | 2022-01-11 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
CN106074591B (en) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | RNA interference in ocular symptoms |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
SI2563920T1 (en) | 2010-04-29 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
SG185027A1 (en) | 2010-05-03 | 2012-11-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
JP5866106B2 (en) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | Method for producing enteroendocrine cells that produce and secrete insulin |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
RU2585229C2 (en) | 2010-05-26 | 2016-05-27 | Курна, Инк. | Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1 |
CA3102008A1 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
RU2611190C2 (en) | 2010-07-14 | 2017-02-21 | Курна, Инк. | Treatment of diseases related with gene dlg by inhibition of natural antisense transcript of dlg gene |
JP5974012B2 (en) | 2010-10-05 | 2016-08-23 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
ES2640755T3 (en) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
RU2611195C2 (en) | 2010-10-27 | 2017-02-21 | Курна, Инк. | Treatment of interferon-related developmental regulator 1 (ifrd1) associated diseases by inhibition of natural antisense transcript to ifrd1 |
US20140134181A1 (en) | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
CN110123830A (en) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare |
CA2818824A1 (en) | 2010-11-23 | 2012-05-31 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
EP2649182A4 (en) | 2010-12-10 | 2015-05-06 | Alnylam Pharmaceuticals Inc | Compositions and methods for increasing erythropoietin (epo) production |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
KR101697396B1 (en) | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
SG193923A1 (en) | 2011-03-29 | 2013-11-29 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of tmprss6 gene |
WO2012142458A1 (en) | 2011-04-13 | 2012-10-18 | Isis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
KR101970634B1 (en) | 2011-06-02 | 2019-04-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Methods and uses for ex vivo tissue culture systems |
ES2653247T3 (en) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene |
CA2839437A1 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
CA3191066A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
EP3564393A1 (en) | 2011-06-21 | 2019-11-06 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
EP3388068A1 (en) | 2011-06-21 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | Composition and methods for inhibition of expression of protein c (proc) genes |
EP4134433A1 (en) | 2011-06-23 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP2724156B1 (en) | 2011-06-27 | 2017-08-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
CN108410868A (en) | 2011-09-20 | 2018-08-17 | Ionis制药公司 | The antisense of GCGR expression is adjusted |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
KR20140084232A (en) | 2011-10-25 | 2014-07-04 | 아이시스 파마수티컬즈 인코포레이티드 | Antisense modulation of gccr expression |
CA2867262C (en) | 2012-03-15 | 2021-03-16 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
WO2014041179A1 (en) | 2012-09-17 | 2014-03-20 | Chemedest Ltd. | Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists |
US9566325B2 (en) | 2013-01-07 | 2017-02-14 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type-2 infections |
US10052364B2 (en) | 2013-03-15 | 2018-08-21 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
EP3708184A1 (en) | 2013-03-27 | 2020-09-16 | The General Hospital Corporation | Methods and agents for treating alzheimer s disease |
EP2994167B1 (en) | 2013-05-06 | 2020-05-06 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
EP3007704B1 (en) | 2013-06-13 | 2021-01-06 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
US11236338B2 (en) | 2013-09-05 | 2022-02-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
EP3047023B1 (en) | 2013-09-19 | 2019-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for inhibiting jc virus (jcv) |
EP3052626A1 (en) | 2013-10-02 | 2016-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
TW202310853A (en) | 2013-10-04 | 2023-03-16 | 美國西奈山伊坎醫學院 | Compositions and methods for inhibiting expression of the alas1 gene |
RU2744194C2 (en) | 2013-12-02 | 2021-03-03 | Фио Фармасьютикалс Корп | Cancer immunotherapy |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
AU2015214264B2 (en) | 2014-02-04 | 2018-12-20 | Curis, Inc. | Mutant Smoothened and methods of using the same |
CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
JP7175608B2 (en) | 2014-11-19 | 2022-11-21 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Osteocalcin as a treatment for age-related frailty |
TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
WO2016100716A1 (en) | 2014-12-18 | 2016-06-23 | Vasant Jadhav | Reversirtm compounds |
CA2974369A1 (en) | 2015-01-20 | 2016-07-28 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
EP3302497A4 (en) | 2015-06-01 | 2019-01-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
WO2017007825A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
WO2017007813A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
CA2989970A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
MA45819A (en) | 2015-10-09 | 2018-08-15 | Sarepta Therapeutics Inc | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCLE DYSTROPHY AND RELATED DISORDERS |
CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
AU2016349954B2 (en) | 2015-11-05 | 2022-08-25 | Antisense Therapeutics Ltd | Mobilizing leukemia cells |
EP3445405A4 (en) | 2016-04-18 | 2019-12-18 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
US10994025B2 (en) | 2017-05-12 | 2021-05-04 | Massachusetts Institute Of Technology | Argonaute protein-double stranded RNA complexes and uses related thereto |
CN110832077A (en) | 2017-07-06 | 2020-02-21 | 箭头药业股份有限公司 | RNAi agents for inhibiting α -ENaC expression and methods of use |
BR112020002280A2 (en) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | pharmacological compound and purification methods |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
JP2021520781A (en) | 2018-04-06 | 2021-08-26 | チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation | Compositions and Methods for Somatic Cell Reprogramming and Imprinting Modulation |
EP3837367A1 (en) | 2018-08-16 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2020113135A1 (en) | 2018-11-29 | 2020-06-04 | Flagship Pioneering Innovations V, Inc. | Methods of modulating rna |
JP2022546570A (en) | 2019-09-03 | 2022-11-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibiting expression of the LECT2 gene |
EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
BR112022020145A2 (en) | 2020-04-06 | 2023-01-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR SILENCING THE MYOC EXPRESSION |
TW202204617A (en) | 2020-04-07 | 2022-02-01 | 美商艾爾妮蘭製藥公司 | Compositions and methods for silencing scn9a expression |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
EP4326873A1 (en) | 2021-04-22 | 2024-02-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4429008B1 (en) * | 1981-12-10 | 1995-05-16 | Univ California | Thiol reactive liposomes |
US4847080A (en) * | 1984-03-07 | 1989-07-11 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers |
US5059421A (en) * | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
ES2032776T3 (en) * | 1986-05-20 | 1993-03-01 | Wako Pure Chemical Industries, Ltd. | NEW LIPOSOMES FUNCTIONALIZED AND A PROCEDURE FOR THEIR PRODUCTION. |
US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
JPH01249717A (en) * | 1988-03-30 | 1989-10-05 | Fuji Photo Film Co Ltd | Production of liposome |
JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5045451A (en) * | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE69110897T2 (en) * | 1990-10-09 | 1995-11-30 | Vestar Inc | INHIBIT OF VIRAL REPLICATION. |
JP3220180B2 (en) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
-
1993
- 1993-01-22 JP JP02765193A patent/JP3351476B2/en not_active Expired - Fee Related
-
1994
- 1994-01-19 US US08/182,832 patent/US5556948A/en not_active Expired - Fee Related
- 1994-01-20 ES ES94100819T patent/ES2140473T3/en not_active Expired - Lifetime
- 1994-01-20 EP EP94100819A patent/EP0607978B1/en not_active Expired - Lifetime
- 1994-01-20 DE DE69421631T patent/DE69421631T2/en not_active Expired - Fee Related
- 1994-01-20 CA CA002113914A patent/CA2113914C/en not_active Expired - Fee Related
-
1996
- 1996-01-24 US US08/590,601 patent/US5686101A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3351476B2 (en) | 2002-11-25 |
DE69421631D1 (en) | 1999-12-23 |
ES2140473T3 (en) | 2000-03-01 |
CA2113914A1 (en) | 1994-07-23 |
US5556948A (en) | 1996-09-17 |
DE69421631T2 (en) | 2000-06-21 |
US5686101A (en) | 1997-11-11 |
EP0607978B1 (en) | 1999-11-17 |
EP0607978A1 (en) | 1994-07-27 |
JPH06220070A (en) | 1994-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2113914C (en) | Phospholipid derivative and liposome containing it | |
EP0526700B1 (en) | Drug-containing protein-bonded liposome | |
US5478860A (en) | Stable microemulsions for hydrophobic compound delivery | |
US7135177B2 (en) | Immunoliposomes that optimize internalization into target cells | |
CA2137297C (en) | Reactive vesicle and functional substance-fixed vesicle | |
US4275000A (en) | Peptide macromolecular complexes | |
JP2005097320A (en) | Enhanced circulation effector composition and method | |
EP1369132A1 (en) | Oxaliplatin containing liposome preparation | |
JP2021500412A (en) | Ligand-drug-complex containing single molecular weight polysarcosine | |
KR19990022453A (en) | Method for preparing monomeric calicheamicin derivative / carrier conjugate | |
KR20070006828A (en) | Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances | |
EP0903152B1 (en) | Bifunctional water-soluble polymer derivative and complex containing it | |
HU210147B (en) | Process for producing antibody-drug conjugates and pharmaceutical compositions containing them | |
JP3759759B2 (en) | Liposomes and drug carriers | |
KR20090078512A (en) | Liposome for cancer cell-specific delivary of anti-cancer drug | |
JP3521925B2 (en) | Phospholipid derivatives | |
US20080069867A1 (en) | Diagnostic and/or Remedy for Ovarian Cancer | |
JP3341487B2 (en) | Reactive endoplasmic reticulum, endoplasmic reticulum modifier and production method | |
JPH08117586A (en) | Reactive endoplasmic reticulum, endoplasmic reticulum modifier and preparation of the same | |
JPH0390037A (en) | Liposome pharmaceutical | |
MURCIA UNIV (SPAIN) | International Workshop on Membrane Biotechnology and Membrane Biomaterials (4th) Held in La Manga, Murcia, Spain on 29 May-2 June 1991. | |
JPH092975A (en) | Reactive endoplasmic reticulum-forming agent and reactive endoplasmic reticulum | |
JPH0499718A (en) | Production of surface-modifiable liposome and surface-modified liposome | |
JPH07277955A (en) | Liposome | |
DD297164A5 (en) | LONG-LINKED DI (ACYLOXY) DIALKYLSILANE, DI (ACYLOXY) DIARYLSILANE, DI (ACYLOXY) DIALKOXYSILANE AND TETRA (ACYLOXY) SILANES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE FOR THE PRODUCTION OF VESICLES, VESICLES MANUFACTURED FROM THEM (SIOSOMES) AND THEIR USE AS SUPPLEMENTS OF ACTIVE INGREDIENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |